Momenta Seizes on Sialix mAb Therapeutic Program
By Marie Powers
Thursday, October 4, 2012
Sialix Inc. raised its biotech cred by inking an option agreement to license an undisclosed monoclonal antibody (mAb) therapeutic program with Momenta Pharmaceuticals Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.